{
    "clinical_study": {
        "@rank": "115931", 
        "acronym": "FEC-TH", 
        "arm_group": {
            "arm_group_label": "People with liver transplantation", 
            "arm_group_type": "Experimental", 
            "description": "People with liver transplantation over 2 years following treatment with immunosuppression including cyclosporine or tacrolimus."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety of extracorporeal photopheresis in\n      patients with long-standing liver transplantation subjected to a progressive reduction of\n      immunosuppression by complications arising from its use."
        }, 
        "brief_title": "Extracorporeal Photopheresis in Liver Transplantation. Phase II Clinical Trial in Safety and Efficacy in Patients With Gradual Decrease of Immunosuppression.", 
        "condition": [
            "Liver Transplantation", 
            "Immunosuppression"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Have been receiving liver transplant two years ago.\n\n          -  Be 18 years or older.\n\n          -  Treatment with immunosuppression including cyclosporine or tacrolimus.\n\n          -  Having a normal liver function in the last year\n\n          -  Not have suffered acute rejection in the last year and have no chronic rejection\n\n          -  Submit any significant side effects from medication immunosuppressive (hypertension,\n             creatinine greater than 1.7 mgDl, diabetes, morbid obesity, osteoporosis,\n             hyperlipidemia, severe hirsutism, neurotoxicity novo malignancy, etc.)\n\n          -  Etiology of underlying disease: alcoholic cirrhosis with or without hepatocarcinoma,\n             metabolic diseases, amyloidotic polyneuropathy family, biliary atresia, fulminant\n             hepatitis non-A, non-B, non-C, cirrhosis cryptogenic and generally causes no viral or\n             autoimmune.\n\n          -  Patients offering sufficient guarantees of adherence to protocol\n\n          -  Patients who give written informed consent for participate in the study.\n\n          -  It is necessary that the patient meets all inclusion criteria.\n\n        Exclusion Criteria:\n\n          -  Underlying disease of the autoimmune (primary sclerosing cholangitis, autoimmune\n             cirrhosis, primary biliary cirrhosis) or epatocarcinoma about cirrhosis of viral or\n             autoimmune.\n\n          -  Patients with chronic rejection, or acute rejection in the last year.\n\n          -  Patients with liver retransplantation.\n\n          -  patients with history of hypersensitivity or idiosyncratic reactions to methoxsalen,\n             psoralen the compounds or any of the excipients.\n\n          -  patients with melanoma, cutaneous basal cell carcinoma or squamous cell coexistent.\n\n          -  Patients with aphakia.\n\n          -  Patients taking Oxoralen.\n\n          -  Pregnant women or nursing mothers, or adults of childbearing age not using effective\n             contraception.\n\n          -  Participation in another clinical trial.\n\n          -  Inability to understand informed consent."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01824368", 
            "org_study_id": "FEC-TH", 
            "secondary_id": "2012-000633-39"
        }, 
        "intervention": {
            "arm_group_label": "People with liver transplantation", 
            "description": "The FEC will be held in the Cellex (Therakos), and authorized device in routine use in our unit for performing FEC in the treatment of graft-versus-host and cutaneous T-cell lymphoma. After performing a blood count, will connect the patient to Cellex through a central or peripheral.\n1500 mL typically be processed peripheral blood mononuclear fraction obtained by apheresis process. Then be added Uvadex (8-metoxipsolareno, 0.017 mL / mL) to the mononuclear fraction bag and proceed to photoactivation with UVA radiation.\nFinally the photoactivated product is again infuse the patient. It will monitor the final blood count to assess hemoglobin and platelets. The entire procedure is performed in a single step and closed mode, with Cellex.", 
            "intervention_name": "Extracorporeal Photopheresis Procedure (FEC)", 
            "intervention_type": "Procedure"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 26, 2013", 
        "link": [
            {
                "description": "Red de Terapia Celular (TerCel)", 
                "url": "http://www.red-tercel.com"
            }, 
            {
                "description": "Fundaci\u00f3n para la Formaci\u00f3n e Investigaci\u00f3n Sanitarias Regi\u00f3n de Murcia", 
                "url": "http://www.ffis.es"
            }, 
            {
                "description": "Servicio Murciano de Salud", 
                "url": "http://www.murciasalud.es"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "El Palmar", 
                    "country": "Spain", 
                    "state": "Murcia", 
                    "zip": "30120"
                }, 
                "name": "University Hospital Virgen de la Arrixaca"
            }
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "1", 
        "official_title": "FOTOAFERESIS EXTRACORP\u00d3REA EN EL TRASPLANTE HEP\u00c1TICO. ENSAYO CLINICO EN FASE II DE SEGURIDAD Y EFICACIA EN PACIENTES CON RETIRADA PROGRESIVA DE LA INMUNOSUPRESI\u00d3N", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "Spain: Spanish Agency of Medicines", 
                "Spain: Ministry of Health"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "adverse event rate and rate of transplant rejection", 
            "safety_issue": "Yes", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01824368"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Red de Terapia Celular", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Spanish National Health System", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Faculty of Medicine. University of Murcia.", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University Hospital Virgen de la Arrixaca.", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Health Service of Murcia.", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Fundaci\u00f3n para la Formaci\u00f3n e Investigaci\u00f3n Sanitarias de la Regi\u00f3n de Murcia", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Red de Terapia Celular", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}